Tetranedron Lett. Author manuscript; available in PMC 2013 July 22.

Published in final edited form as:

Tetrahedron Lett. 2008 January 7; 49(2): 286–288. doi:10.1016/j.tetlet.2007.11.069.

# Progress towards the synthesis of Papuaforin A: Selective formation of $\alpha$ -bromoenones from silyl enol ethers

### George A. Kraus\* and Insik Jeon

Department of Chemistry, Iowa State University, Ames, IA 50011

#### **Abstract**

The selective one-pot conversion of enol silyl ethers into  $\alpha$ -bromoenones allows a direct preparation of a tricyclic intermediate to papuaforin A.

The antidepressant activity of *Hypericum perforatum*, commonly known as St. John's wort, has drawn much attention.1-4 St. John's wort is used as a natural remedy to treat moderate to mild depression. Studies of the constituents of St. John's wort and other plants from the family Guttiferae identified a novel class of natural products, polycyclic polyprenylated acylphloroglucinols (PPAPs). Due to their significant biological activity and challenging structures, members of this class have become attractive synthetic targets and are shown in Figure 1.5 Hyperforin (1) was isolated from *Hypericum perforatum*,6 and is thought to be responsible for the antidepressant and antibacterial activities of St. John's wort.6-10 Nemorosone (2) shows cytotoxic activity against epithelioid carcinoma (HeLa), epidermoid carcinoma (Hep-2), prostate cancer (PC-3) and central nervous system cancer (U251).11 Papuaforin A (3), extracted from *Hypericum papuanum* (Papua New Guinea), shows moderate cytotoxic activity toward the KB cell line (IC<sub>50</sub> =  $4.9 \,\mu\text{g/mL}$ ) and modest antibacterial activity against Micrococcus luteus, Staphylococcus epidermidis, and Bacillus cereus.12 As part of a program to synthesize bioactive constituents from Hypericum and Echinacea species, 13 we report herein the construction of an advanced intermediate for the synthesis of papuaforin A.

The 2,2-dimethyl-2*H*-pyran ring contained in **3** is formed by cyclization of a prenyl side chain onto the  $\beta$ -diketone. Initial experiments to prepare this  $\beta$ -diketone focused on the allylic bromination of an alkene to produce the tribromide shown below which readily hydrolyzed to a beta-bromo enone. Unfortunately, when more highly congested systems were evaluated (R = alkyl), the enone (the product of dibromination followed by hydrolysis) rather than the  $\beta$ -bromo enone became the major product.

In order to generate an  $\alpha$ -bromoenone, the TIPS enol ether 6 was prepared as shown in Scheme 1 from keto ester 414 by Michael addition followed by Birch reduction/

<sup>\*</sup>Author to whom correspondence should be addressed; gakraus@iastate.edu, Iowa State University, Department of Chemistry, Ames, IA 50011, USA. Tel. +1 515-294-7794; Fax: +1 515-294-0105.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

cyclization15 to generate diol **5**. This compound was oxidized with PCC and the resulting diketone was silylated to provide **6** using KH and triisopropylsilyl triflate.16

Initial model studies were conducted on silyl enol ether **7**, prepared from the diketo ester and triisopropylsilyl triflate. As shown in Scheme 2, the radical bromination of **7** under thermal conditions afforded a mixture of enone **8** and  $\alpha$ -bromoenone **9** in a 2:1 ratio in 60% yield. In contrast, bromination under photochemical conditions generated  $\beta$ -bromoenone **10** in 63% yield, as evidenced by the resonance at 7.02 ppm. Photochemical bromination of **11** produced  $\alpha$ -bromo ketone **12** in 70% yield. Its structure was supported by a resonance at 7.64. The additional steps involved in forming the carbonate and later regenerating the allyl group, prompted us to examine the selective bromination of **6**, the precursor to **11**. The radical bromination under photochemical conditions was not clean, but the thermal conditions allowed a 75% yield of  $\alpha$ -bromoketone **13**.17

The approach to **3** from **13** began with the Sonogashira reaction shown in Scheme 3. This reaction failed when conducted under the typical reaction conditions; however, when diethylamine was used as the solvent, a 70% yield of acetylenic ketone **14** was obtained. Reduction18 of the triple bond to afford **15**19 was achieved in 50% yield. The assignment of the stereochemistry of the hemiketal is tentative, but the resistance of the hydroxyl group to acetylation supports the assignment of the hydroxyl group to the more hindered face. Pyridinium chlorochromate oxidation20 has been used to convert a tertiary allylic alcohol to the rearranged enone. Unfortunately, PCC oxidation of **15** did not produce the desired ketone **16**.

The radical bromination of enol silyl ethers generates  $\alpha$ -bromoenones in good yields. Compound 13 was transformed into a tricyclic intermediate to 3 via Sonogashira coupling and reduction. The conversion of 15 into 16 by rearrangement followed by oxidation is in progress.

## **Acknowledgments**

We thank the National Institutes of Health (grant P01 ES12020) and the Office of Dietary Supplements for partial financial support through the Center for Research on Botanical Dietary Supplements at Iowa State University.

#### References

- Barnes J, Anderson LA, Phillipson JD. J Pharm Pharmacol. 2001; 53:583. [PubMed: 11370698]
  Muller WE. Pharmacol Res. 2003; 47:101. [PubMed: 12543057]
- 2. Verotta L. Phytochem Rev. 2002; 1:389.
- 3. Rodriguez-Landa JF, Contreras CM. Phytomedicine. 2003; 10:688. [PubMed: 14692732]
- Salatino A, Teixeira EW, Negri G, Message D. Evidence-Based Complement. Alternat Med. 2005;
  2:33
- Nicolaou KC, Carenzi GEA, Jeso V. ACIE. 2005; 44:3895–3899.Ciochina R, Grossman RB. Org Lett. 2003; 5:4619–4621. [PubMed: 14627398] Kraus GA, Nguyen TH, Jeon I. Tetrahedron Lett. 2003; 44:659–661.Mehta G, Bera MK. Tetrahedron Lett. 2004; 45:1113–1116.Nicolaou KC, Pfefferkorn JA, Kim S, Wei HX. J Am Chem Soc. 1999; 121:4724.Siegel DR, Danishefsky S. J Am Chem Soc. 2006; 128:1048–1049. [PubMed: 16433500] Kuramochi A, Usuda H, Yamatsugu K, Kanai M, Shibasaki M. J Am Chem Soc. 2005; 127:14200–14201. [PubMed: 16218611] Spessard SJ, Stoltz BM. Org Lett. 2002; 4:1943–1946. [PubMed: 12027653]
- Gurevich AI, Dobrynin VN, Kolosov MN, Poprako SA, Ryabova I, Chernov BK, Debrentzeva NA, Aizeman BE, Garagulya AD. Antibiotiki (Moscow). 1971; 16:510.
- 7. Mennini T, Gobbi M. Life Sci. 2004; 75:1021. [PubMed: 15207650]
- 8. Adam P, Arigoni D, Bacher A, Eisenreich W. J Med Chem. 2002; 45:4786. [PubMed: 12361406]

9. (a) Kaehler ST, Sinner C, Chatterjee SS, Philippu A. Neurosci Lett. 1999; 262:199. [PubMed: 10218890] (b) Muller WE, Singer A, Wonnemann M. Pharmacopsychiatry. 2001; 34(Suppl 1):S98. [PubMed: 11518085]

- Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Pharmacopsychiatry. 1998;
  31(Suppl 1):16. [PubMed: 9684943]
- 11. Cuesta-Rubio O, Velez-Castro H, Frontana-Uribe BA, Cardenas. J Phytochemistry. 2001; 57:279–283. Grossman RB, Jacobs H. Tetrahedron Lett. 2000; 41:5165–5169.
- 12. Winkelmann K, Heilmann J, Zerbe O, Rali T, Sticher O. J Nat Prod. 2001; 64:701–706. [PubMed: 11421727]
- Kraus GA, Bae J, Kim J. Synthetic Communications. 2007; 37:1251–1257. [PubMed: 17917688]
  Kraus GA, Bae J, Wu L, Wurtele E. Molecules. 2007; 12:406–414. [PubMed: 17851399]
  Kraus GA, Jeon I. Org Lett. 2006; 8:5315–5316. [PubMed: 17078706]
- 14. Compound 4 was prepared from 3-methoxy-2,5,5-trimethylcyclohexenone ( Clark RD, Ellis JE, Heathcock CH. Synth Commun. 1973; 3:347–54.) by alkylation (LiTMP, allyl bromide, THF), LAH reduction followed by 10% aq. HCl, and carboalkoxylation (LiTMP, CNCO<sub>2</sub>Me).
- 15. Boeckman RK Jr, Arvanitis A, Voss ME. J Am Chem Soc. 1989; 111:2737–2739.
- 16. Representative experimental for conversion of ketones to bromoenones: To a stirred solution of KH (2 g, 30% in mineral oil, 15 mmol, mineral oil was removed with hexane prior to use) in THF (20 mL) were added a solution of the diketone (1.46 g, 5 mmol) and triisopropylsilyl triflate (2.7 mL, 10 mmol) in THF (10 mL), and stirred for 12 h. The reaction was diluted with saturated NaHCO<sub>3</sub> (20 mL) and extracted with ethyl acetate (15 mL × 3). The combined organic phase was washed with water, brine, and dried over MgSO<sub>4</sub>. The residue was purified by silica gel chromatography (EtOAc/hexanes, 1: 30) to give the silylated compound. This compound was dissolved in CCl<sub>4</sub> (20 mL), followed by the addition of NBS (3.56 g, 10 mmol) and AIBN (82 mg, 0.5 mmol). The mixture was boiled for 1 h, cooled to rt, diluted with aqueous NaHCO3 and extracted with CH<sub>2</sub>Cl<sub>2</sub> (20 mL × 2). The combined organic layers were washed with brine and dried over MgSO<sub>4</sub>. The residue was purified by chromatography on silica gel (EtOAc/hexanes, 1: 7) to furnish 13 (1.31 g, 71%): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) 87.64 (s, 1H), 5.67-5.53 (m, 1H), 5.04-4.98 (m, 2H), 3.80 (s, 3H), 2.31-2.25 (m, 1H), 2.02-1.96 (m, 1H), 1.74-1.63 (m, 2H), 1.51-1.41 (m, 1H), 1.31 (s, 3H), 1.20 (s, 3H), 1.17 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) 8201.6, 191.5, 167.6, 146.4, 136.1, 125.5, 117.7, 71.1, 63.2, 53.0, 45.0, 42.0, 40.4, 34.0, 24.1, 16.7, 16.6; HRMS *m/z* calcd for 368.0623, found 368.0629.
- 17. Photochemical bromination was done in a Rayonet reactor in a Pyrex test tube under argon in CCl<sub>4</sub> with substrate (1 equiv.), NBS (2 equiv.) and catalytic AIBN. It was followed by TLC.
- 18. Durant A, Delplancke JL, Libert V, Reisse J. Eur J Org Chem. 1999:2845–2851.
- 19. Spectra for 15: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 86.19 (d, *J* = 10.4 Hz, 1H), 5.89 (d, *J* = 10.0 Hz, 1H), 5.72-5.62 (m, 1H), 5.69 (s, 1H), 5.03-4.97 (m, 2H), 3.72 (s, 3H), 2.39 (dd, *J* = 14.4, 4.8 Hz, 1H), 2.25 (s, 1H), 2.23-2.17 (m, 1H), 1.86-1.78 (m, 1H), 1.64-1.51 (m, 2H), 1.43 (s, 3H), 1.30 (s, 3H), 1.18 (s, 3H), 1.10 (s, 3H), 1.06 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) 8207.1, 137.6, 136.3, 134.4, 122.2, 120.2, 116.2, 97.5, 73.5, 68.1, 56.0, 52.3, 46.4, 40.4, 39.3, 34.5, 31.0, 29.1, 23.2, 17.0, 15.5; HRMS *m/z* calcd for 374.2093, found 374.2098.
- 20. Dauben WG, Michno DM. J Org Chem. 1977; 42:682.

**Figure 1.** Polycyclic polyprenylated acylphloroglucinols (PPAPs)

- 1. Methyl acrylate, tBuOK
- 2. 15 equiv. *t*-BuOH 6 equiv. Na, NH<sub>3</sub> 85%
- PCC, Celite CH<sub>2</sub>Cl<sub>2</sub>, 87%
   TIPSOTf, KH
- OTIPS

**Scheme 1.** Synthesis of silyl enol ether **6** 

Scheme 2. Synthesis of bromoenones

**Scheme 3.** Synthesis of an advanced intermediate